Form D · Biotechnology
Helicore Bioventures I, Inc.
New York, NY · CIK 0002008794
Offering snapshot reported Jan 19, 2024 · SEC filing
- Reported sold
- $15M Offering amount: $65M
- Investors reported
- 8 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 10, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 19, 2024 | Initial | $14,999,997 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-502956
The Total Offering Amount and Total Amount Sold includes the conversion of $5,192,307.36 in outstanding convertible securities. The remaining $50,000,000 to be sold is contingent upon the achievement of certain business milestones.
Source: Form D, filed Jan 19, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Patrick R Crutcher | Executive, Promoter |
| Rishi Gupta | Director |
| Jing Liang | Director, Executive, Promoter |
| Brian Liu | Director |
| Hugh Young Rienhoff, Jr. | Director, Promoter |
| Carl Rizzuto | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
619 W 54 Th Street, Suite 702
New York, NY, 10019
New York, NY, 10019